**FORM 4**

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*

   WANG HUIMIN
   ONE EDWARDS WAY
   IRVINE CA 92614

2. Issuer Name and Ticker or Trading Symbol

   Edwards Lifesciences Corp [ EW ]

3. Date of Earliest Transaction (Month/Day/Year)

   06/11/2020

4. If Amendment, Date of Original Filed (Month/Day/Year)

   06/11/2020

5. Relationship of Reporting Person(s) to Issuer

   Director 10% Owner
   X Officer (give title below)
   CVP, Japan & Intercontinental
   Other (specify below)

6. Individual or Joint/GROUP Filing (Check Applicable Line)

   X Form filed by One Reporting Person
   Form filed by More than One Reporting Person

---

### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

<table>
<thead>
<tr>
<th>Title of Security (Instr. 3)</th>
<th>Transaction Date (Month/Day/Year)</th>
<th>Deemed Execution Date, if any (Month/Day/Year)</th>
<th>Transaction Code (Instr. 8)</th>
<th>Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)</th>
<th>Amount (A) or (D)</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common Stock</td>
<td>06/11/2020</td>
<td></td>
<td>M(1)</td>
<td>A</td>
<td>11,649</td>
<td>$13.98</td>
</tr>
<tr>
<td>Common Stock</td>
<td>06/11/2020</td>
<td></td>
<td>S(1)</td>
<td>D</td>
<td>84</td>
<td>$72.59</td>
</tr>
<tr>
<td>Common Stock</td>
<td>06/11/2020</td>
<td></td>
<td>S(1)</td>
<td>D</td>
<td>3,287</td>
<td>$72.427</td>
</tr>
<tr>
<td>Common Stock</td>
<td>06/11/2020</td>
<td></td>
<td>S(1)</td>
<td>D</td>
<td>8,362</td>
<td>$71.253</td>
</tr>
</tbody>
</table>

---

### Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

<table>
<thead>
<tr>
<th>Title of Derivative Security (Instr. 3)</th>
<th>Conversion or Exercise Price of Derivative Security</th>
<th>Transaction Date (Month/Day/Year)</th>
<th>Deemed Execution Date, if any (Month/Day/Year)</th>
<th>Transaction Code (Instr. 8)</th>
<th>Number of Derivative Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)</th>
<th>Date Exercisable</th>
<th>Expiration Date</th>
<th>Title of Security Underlying Derivative Security (Instr. 3 and 4)</th>
<th>Price of Derivative Security (Instr. 5)</th>
<th>Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3, 4 and 5)</th>
<th>Ownership Form: Direct (D) or Indirect (I) (Instr. 4)</th>
<th>Nature of Indirect Beneficial Ownership (Instr. 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Employee Stock Option (Right to Acquire)</td>
<td>$13.98</td>
<td>06/11/2020</td>
<td></td>
<td>M(1)</td>
<td>11,649</td>
<td>05/08/2015</td>
<td>05/07/2021</td>
<td>Common Stock</td>
<td>$0.0000</td>
<td>93,204</td>
<td>D</td>
<td></td>
</tr>
</tbody>
</table>

---

### Explanation of Responses:

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 28, 2020.

2. This transaction was executed in multiple trades at prices ranging from $71.90 to $72.59. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.

3. This transaction was executed in multiple trades at prices ranging from $70.88 to $72.59. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

On May 29, 2020, the common stock of Edwards Lifesciences Corporation split 3-for-1, resulting in the reporting person's ownership of additional shares of common stock and stock options. This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.

Linda J. Park, Attorney-in-Fact 06/11/2020

**Signature of Reporting Person**  **Date**

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).


Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.